Skip to content

Study · Not a test of the peptide alone · 2025

6 results

Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series.

Tinsley GM, Nadolsky S

SAGE open medical case reports16 Oct 2025Cited by 9 (Europe PMC)

PMID41122508 (opens in a new tab)PMCIDPMC12536186 (opens in a new tab)DOI10.1177/2050313x251388724 (opens in a new tab)PepBankPUB-41122508
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In three patients treated with semaglutide or tirzepatide (drug per patient not stated), body weight fell by 13.2% to 33.0%.

    In plain wordsIn three patients treated with semaglutide or tirzepatide, body weight fell by 13.2% to 33.0%.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change
    Study

    n = 3

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight change
    −33%
    case 1
    Weight change
    −26.8%
    case 2
    Weight change
    −13.2%
    case 3

    Source sentences

    Summary
    Changes in weight, fat mass, and lean soft tissue were: -33.0%, -53.4%, and -6.9% (case 1); -26.8%, -61.6%, and +2.5% (case 2); and -13.2%, -46.9%, and +5.8% (case 3).
    1 context sentence
    Summary · context
    This case series describes three patients (two female, one male; body mass index: 32.9-51.9 kg m-2) who prioritized lean soft tissue preservation strategies during treatment with semaglutide or tirzepatide.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Tirzepatide aloneCase report or seriesEfficacy outcome

    In three patients treated with semaglutide or tirzepatide (drug per patient not stated), body weight fell by 13.2% to 33.0%.

    In plain wordsIn three patients treated with semaglutide or tirzepatide, body weight fell by 13.2% to 33.0%.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight change
    Study

    n = 3

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight change
    −33%
    case 1
    Weight change
    −26.8%
    case 2
    Weight change
    −13.2%
    case 3

    Source sentences

    Summary
    Changes in weight, fat mass, and lean soft tissue were: -33.0%, -53.4%, and -6.9% (case 1); -26.8%, -61.6%, and +2.5% (case 2); and -13.2%, -46.9%, and +5.8% (case 3).
    1 context sentence
    Summary · context
    This case series describes three patients (two female, one male; body mass index: 32.9-51.9 kg m-2) who prioritized lean soft tissue preservation strategies during treatment with semaglutide or tirzepatide.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  3. 03HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In three patients treated with semaglutide or tirzepatide (drug per patient not stated), fat mass fell by 46.9% to 61.6%.

    In plain wordsIn three patients treated with semaglutide or tirzepatide, fat mass fell by 46.9% to 61.6%.

    Peptide
    Semaglutide
    Outcome
    DecreaseFat mass change
    Study

    n = 3

    Outcome group
    Body composition · Metabolic and weight

    Measurements

    Fat mass change
    −53.4%
    case 1
    Fat mass change
    −61.6%
    case 2
    Fat mass change
    −46.9%
    case 3

    Source sentences

    Summary
    Changes in weight, fat mass, and lean soft tissue were: -33.0%, -53.4%, and -6.9% (case 1); -26.8%, -61.6%, and +2.5% (case 2); and -13.2%, -46.9%, and +5.8% (case 3).
    1 context sentence
    Summary · context
    This case series describes three patients (two female, one male; body mass index: 32.9-51.9 kg m-2) who prioritized lean soft tissue preservation strategies during treatment with semaglutide or tirzepatide.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04HumanNot a test of Tirzepatide aloneCase report or seriesEfficacy outcome

    In three patients treated with semaglutide or tirzepatide (drug per patient not stated), fat mass fell by 46.9% to 61.6%.

    In plain wordsIn three patients treated with semaglutide or tirzepatide, fat mass fell by 46.9% to 61.6%.

    Peptide
    Tirzepatide
    Outcome
    DecreaseFat mass change
    Study

    n = 3

    Outcome group
    Body composition · Metabolic and weight

    Measurements

    Fat mass change
    −53.4%
    case 1
    Fat mass change
    −61.6%
    case 2
    Fat mass change
    −46.9%
    case 3

    Source sentences

    Summary
    Changes in weight, fat mass, and lean soft tissue were: -33.0%, -53.4%, and -6.9% (case 1); -26.8%, -61.6%, and +2.5% (case 2); and -13.2%, -46.9%, and +5.8% (case 3).
    1 context sentence
    Summary · context
    This case series describes three patients (two female, one male; body mass index: 32.9-51.9 kg m-2) who prioritized lean soft tissue preservation strategies during treatment with semaglutide or tirzepatide.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  5. 05HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In three patients treated with semaglutide or tirzepatide (drug per patient not stated) who used lean-tissue preservation strategies, lean soft tissue fell in one patient and rose in two.

    In plain wordsIn three patients on semaglutide or tirzepatide who used lean-tissue strategies, lean soft tissue fell in one patient and rose in two.

    Peptide
    Semaglutide
    Outcome
    MixedLean soft tissue change
    Study

    n = 3

    Outcome group
    Body composition · Metabolic and weight

    Measurements

    Lean soft tissue change
    −6.9%
    case 1
    Lean soft tissue change
    2.5%
    case 2
    Lean soft tissue change
    5.8%
    case 3

    Source sentences

    Summary
    Changes in weight, fat mass, and lean soft tissue were: -33.0%, -53.4%, and -6.9% (case 1); -26.8%, -61.6%, and +2.5% (case 2); and -13.2%, -46.9%, and +5.8% (case 3). Accordingly, one patient lost 8.7% of weight as lean soft tissue, while two increased lean soft tissue.
    1 context sentence
    Summary · context
    This case series describes three patients (two female, one male; body mass index: 32.9-51.9 kg m-2) who prioritized lean soft tissue preservation strategies during treatment with semaglutide or tirzepatide.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  6. 06HumanNot a test of Tirzepatide aloneCase report or seriesEfficacy outcome

    In three patients treated with semaglutide or tirzepatide (drug per patient not stated) who used lean-tissue preservation strategies, lean soft tissue fell in one patient and rose in two.

    In plain wordsIn three patients on semaglutide or tirzepatide who used lean-tissue strategies, lean soft tissue fell in one patient and rose in two.

    Peptide
    Tirzepatide
    Outcome
    MixedLean soft tissue change
    Study

    n = 3

    Outcome group
    Body composition · Metabolic and weight

    Measurements

    Lean soft tissue change
    −6.9%
    case 1
    Lean soft tissue change
    2.5%
    case 2
    Lean soft tissue change
    5.8%
    case 3

    Source sentences

    Summary
    Changes in weight, fat mass, and lean soft tissue were: -33.0%, -53.4%, and -6.9% (case 1); -26.8%, -61.6%, and +2.5% (case 2); and -13.2%, -46.9%, and +5.8% (case 3). Accordingly, one patient lost 8.7% of weight as lean soft tissue, while two increased lean soft tissue.
    1 context sentence
    Summary · context
    This case series describes three patients (two female, one male; body mass index: 32.9-51.9 kg m-2) who prioritized lean soft tissue preservation strategies during treatment with semaglutide or tirzepatide.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.